160 related articles for article (PubMed ID: 31597496)
1. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
[No Abstract] [Full Text] [Related]
2. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat AA; Nelson R; Au T; Biskupiak J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Wu B; Li T; Cai J; Xu Y; Zhao G
BMC Cancer; 2014 Dec; 14():984. PubMed ID: 25526802
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1.
Hisashige A; Sasako M; Nakajima T
BMC Cancer; 2013 Oct; 13():443. PubMed ID: 24079752
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Hagiwara Y; Ohashi Y; Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T;
Eur J Cancer; 2018 Apr; 93():79-88. PubMed ID: 29477795
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Tan C; Peng L; Zeng X; Li J; Wan X; Chen G; Yi L; Luo X; Zhao Z
PLoS One; 2013; 8(12):e83396. PubMed ID: 24340099
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Shimoda M; Kubota K; Shimizu T; Katoh M
Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
Kurihara T; Kobayashi M; Kogo M; Yoneyama K; Ito N; Sunaga T; Konishi K; Imawari M; Tobe T; Kiuchi Y
Gan To Kagaku Ryoho; 2010 Apr; 37(4):659-64. PubMed ID: 20414022
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
13. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial.
Huang J; Liao W; Zhou J; Zhang P; Wen F; Wang X; Zhang M; Zhou K; Wu Q; Li Q
Cancer Manag Res; 2018; 10():4065-4072. PubMed ID: 30323662
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
Maeda A; Boku N; Fukutomi A; Kondo S; Kinoshita T; Nagino M; Uesaka K
Jpn J Clin Oncol; 2008 Mar; 38(3):227-9. PubMed ID: 18272475
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
Roth JA; Carlson JJ
J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
[TBL] [Abstract][Full Text] [Related]
19. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]